22198-Lung Cancer-NA-300

Lung Cancer

(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

  • Details

ClinicalTrials.gov ID: NCT05607550
Diagnosis Type: NA
USOR Number:

  • Address

1580 Beam Avenue
Maplewood, MN 55109
P: (651) 779-7978

Search by practice name, trial titles, indicators and specific disease types.

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.